Trials / Conditions / Overactive Detrusor

Overactive Detrusor

16 registered clinical trials studyying Overactive Detrusor — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Yoga for Treatment of Overactive Bladder in Pediatric Patients NCT05895045	Duke University	N/A
Enrolling By Invitation	Migraine Medication Effects on Urinary Symptoms NCT06212661	The Cleveland Clinic	—
Active Not Recruiting	Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder NCT05977634	Ege University	N/A
Completed	Minimizing Pain During Office Intradetrussor Botox Injection NCT04270526	Boston Urogynecology Associates	Phase 4
Completed	Comparison of Different Treatments for Overactive Bladder Syndrome NCT04197466	Ankara Yildirim Beyazıt University	N/A
Completed	Efficacy of Two Onabotulinum Toxin Doses NCT03388086	Swiss Paraplegic Research, Nottwil	—
Completed	Reproductibility of Cystometry in Multiple Sclerosis Patient NCT03451175	Pierre and Marie Curie University	—
Terminated	Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections NCT03080389	The Cleveland Clinic	—
Completed	Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB NCT02657057	Instituto Médico Tecnológico SL	N/A
Unknown	Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity NCT02009540	Mr HD Flood	Phase 4
Completed	Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia NCT01781117	KYU-SUNG LEE	N/A
Completed	Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity NCT01837654	Assaf-Harofeh Medical Center	N/A
Completed	Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder NCT01192568	AbbVie	Phase 4
Completed	"Swallow my Urine Back" : Inhibition of Detrusor Overactivity by Swallowing Maneuver NCT01408771	Assaf-Harofeh Medical Center	—
Completed	Onabotulinumtoxina Intradetrusorial Injections and NGF Expression NCT01629433	University Of Perugia	—
Terminated	Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity NCT00845338	Bayer	Phase 2